CasaPharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CasaPharma
Largest movements
- Receivables within one year -€10,938
down €10,938 (-100.0%), from €10,938 to €0
- Cash -€2,157
down €2,157 (-14.4%), from €14,978 to €12,821
mainly Trade debts (-€7,412) and Other debts (-€5,000)
- Trade debts -€7,412
down €7,412 (-88.5%), from €8,371 to €960
- Other debts -€5,000
down €5,000 (-27.6%), from €18,103 to €13,103
- Profit (loss) carried forward -€683
down €683 (-3.6%), from -€19,159 to -€19,842
- Gross operating margin -€8,082
down €8,082, from €8,033 to -€49
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €25,915 | €12,821 | -€13,095 | -50.5% |
| Current assets | 29/58 | €25,915 | €12,821 | -€13,095 | -50.5% |
| Amounts receivable within one year | 40/41 | €10,938 | €0 | -€10,938 | -100.0% |
| Trade receivables | 40 | €10,938 | €0 | -€10,938 | -100.0% |
| Cash at bank and in hand | 54/58 | €14,978 | €12,821 | -€2,157 | -14.4% |
| Deferred charges and accrued income | 490/1 | €0 | - | = | |
| Total equity and liabilities | 10/49 | €25,915 | €12,821 | -€13,095 | -50.5% |
| Equity | 10/15 | -€559 | -€1,242 | -€683 | -122.2% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€19,159 | -€19,842 | -€683 | -3.6% |
| Amounts payable | 17/49 | €26,475 | €14,063 | -€12,412 | -46.9% |
| Amounts payable within one year | 42/48 | €26,475 | €14,063 | -€12,412 | -46.9% |
| Trade debts | 44 | €8,371 | €960 | -€7,412 | -88.5% |
| Suppliers | 440/4 | €8,371 | €960 | -€7,412 | -88.5% |
| Other amounts payable | 47/48 | €18,103 | €13,103 | -€5,000 | -27.6% |
| Other operating charges | 640/8 | €528 | €544 | +€16 | +3.0% |
| Gross operating margin | 9900 | €8,033 | -€49 | -€8,082 | |
| Operating profit (loss) | 9901 | €7,505 | -€593 | -€8,098 | |
| Financial charges | 65/66B | €94 | €90 | -€4 | -3.7% |
| Recurring financial charges | 65 | €94 | €90 | -€4 | -3.7% |
| Profit (loss) for the period before taxes | 9903 | €7,411 | -€683 | -€8,095 | |
| Profit (loss) for the period | 9904 | €7,411 | -€683 | -€8,095 | |
| Profit (loss) for the period to be appropriated | 9905 | €7,411 | -€683 | -€8,095 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 4 October 2026 via checked.be.